- Home
- JGH vs AVIR Comparison
JGH vs AVIR Comparison
Compare JGH & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JGH | AVIR |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 292.3M | 266.4M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | JGH | AVIR |
|---|---|---|
| Price | $12.77 | $3.64 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 73.9K | ★ 399.3K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 9.85% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.36 | $2.46 |
| 52 Week High | $12.85 | $4.02 |
Technical Indicators
Market Signals| Indicator | JGH | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 67.35 | 64.65 |
| Support Level | $12.55 | $3.34 |
| Resistance Level | $12.66 | $3.63 |
| Average True Range (ATR) | 0.08 | 0.15 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 95.24 | 86.18 |
Price Performance
Historical ComparisonAbout JGH Nuveen Global High Income Fund of Beneficial Interest
Nuveen Global High Income Fund operates as a diversified closed-end management investment company. The fund's investment objective is to provide a high level of current income. Its securities include U.S. high-yield bonds; non-U.S. high-yield bonds from developed and emerging markets; and other income-producing investments such as preferred and convertible securities.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).